Keyword: Mylan


4. Mylan/Pfizer's Upjohn

Why is Mylan wading deeper into generics with the Pfizer established medicines deal? To hear executives tell it, it's getting a global footprint.
People shaking hands across a desk that has computer and papers on it

The top 10 largest biopharma M&A deals in 2019

Biopharma M&A got a big boost moneywise in 2019. The three largest delivered more than $150 billion, with Bristol-Myers Squibb's $74 billion takeover of Celgene setting a new record. Oncology was still a hot theme, stringing through a whole year of big dealmaking headlines, just as gene therapy gained popularity.